Refractory myasthenia gravis successfully treated with ofatumumab
Corresponding Author
Michael J. Waters
BMBS
Department of Neurology, Royal Adelaide Hospital, Adelaide, South Australia, Australia
Correspondence
Michael J Waters, c/o Department of Neurology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Email: [email protected]
Search for more papers by this authorDeborah Field
MBBS
Department of Neurology, Royal Adelaide Hospital, Adelaide, South Australia, Australia
Search for more papers by this authorJanakan Ravindran
MBBS
Department of Neurology, Royal Adelaide Hospital, Adelaide, South Australia, Australia
Search for more papers by this authorCorresponding Author
Michael J. Waters
BMBS
Department of Neurology, Royal Adelaide Hospital, Adelaide, South Australia, Australia
Correspondence
Michael J Waters, c/o Department of Neurology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Email: [email protected]
Search for more papers by this authorDeborah Field
MBBS
Department of Neurology, Royal Adelaide Hospital, Adelaide, South Australia, Australia
Search for more papers by this authorJanakan Ravindran
MBBS
Department of Neurology, Royal Adelaide Hospital, Adelaide, South Australia, Australia
Search for more papers by this authorCONFLICT OF INTEREST
None of the authors has any conflict of interest to disclose.
REFERENCES
- 1Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S. Myasthenia gravis - autoantibody characteristics and their implications for therapy. Nat Rev Neurol. 2016; 12: 259-268. https://doi.org/10.1038/nrneurol.2016.44.
- 2Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev. 2007; 17: CD005224. https://doi.org/10.1002/14651858.CD005224.pub2.
- 3Tandan R, Hehir MK, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve. 2017; 56: 185-196. https://doi.org/10.1002/mus.25597.
- 4Klein C, Lammens A, Schäfer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013; 5: 22-23. https://doi.org/10.4161/mabs.22771.
- 5Quattrocchi E, Østergaard M, Taylor PC, et al. Safety of repeated open-label treatment courses of intravenous ofatumumab, a human anti-CD20 monoclonal antibody, in rheumatoid arthritis: Results from three clinical trials. PLoS One. 2016; 11:e0157961. https://doi.org/10.1371/journal.pone.0157961.
- 6Wu Y, Wang Y, Gu Y, et al. Safety and efficacy of Ofatumumab in chronic lymphocytic leukemia: a systematic review and meta-analysis. Hematology. 2017; 22: 578-584. https://doi.org/10.1080/10245332.2017.1333974.
- 7Sorensen PS, Lisby S, Grove R, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology. 2014; 82: 573-581. https://doi.org/10.1212/WNL.0000000000000125.
- 8McAdoo SP, Bedi R, Tarzi R, Griffith M, Pusey CD, Cairns TD. Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series. Rheumatology (Oxford). 2016; 55: 1437-1442. https://doi.org/10.1093/rheumatology/kew199.
- 9Burns TM, Conaway M, Sanders DB. The MG composite: a valid and reliable outcome measure for myasthenia gravis. Neurology. 2010; 74: 1434-1440. https://doi.org/10.1212/WNL.0b013e3181dc1b1e.
- 10Masoud S, McAdoo SP, Bedi R, Cairns TD, Lightstone L. Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab. Rheumatology (Oxford). 2018. [Epub ahead of print]. https://doi.org/10.1093/rheumatology/key042.
Citing Literature
